¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¸²ÇÁÁ¾¿¬±¸È¸ CISL34 ÀÓ»ó½ÃÇè ¿¬±¸ÀÚ ¸ðÀÓ : 2023-08-26

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

¸²ÇÁÁ¾¿¬±¸È¸ CISL34 ÀÓ»ó½ÃÇè ¿¬±¸ÀÚ ¸ðÀÓ : 2023-08-26
±³À°ÀÏÀÚ : 2023-08-26
±³À°Àå¼Ò : ¼­¿ï ·Ôµ¥¿ùµåŸ¿ö SKY31 ÄÁº¥¼Ç

±³À°ÁÖÁ¦ : CISL34 ÀÓ»ó½ÃÇè ¿¬±¸ÀÚ ¸ðÀÓ

ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¸²ÇÁÁ¾¿¬±¸È¸

´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581

À̸ÞÀÏ : hematology@kams.or.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú

Âü¼®¿¹»óÀÎ : 60¸í
Èñ¸ÁÆòÁ¡ : 3Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í Àü¹®ÀÇ 50000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 13:00~13:10 Brentuximab vedotin plus cisplatin, cytarabine, and dexamethasone in patients with relapsed  or refractory Hodgkin¡¯s lymphoma who are eligible for transplan ÀÌÁØÈ£(Áß¾ÓÀÇ´ë)

±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 13:10~13:20 Phase II study of Glofitamab, Poseltinib and Lenalidomide in patients with relapsed/refractory diffuse large B cell lymphoma º¯ÀÚ¹Î(¼­¿ïÀÇ´ë )

±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 13:20~13:30 CISL2204: A randomized phase II trial comparing rituximab/bendamustine (RB) alternating with rituximab/bendamustine/cytarabine (RBAC) with RB as induction therapy in elderly patients with newly diagnosed and transplant-ineligible mantle cell lymphoma ÀÓÈ£¿µ(ÀüºÏÀÇ´ë )

±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 13:30~13:40 CISL2208: Duodenal-type follicular lymphoma in Korean population: A multicenter study Á¤Á¾Çå(±¹¸³¾Ï¼¾ÅÍ )

±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 13:40~13:50 Phase II study of lenalidomide-R-CHOP for patients with diffuse large B cell lymphoma Á¶Çü¿ì(¿ï»êÀÇ´ë )

±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 13:50~14:00 Phase II trial of Lenalidomide maintenance after high-dose methotrexate-based immunochemotherapy in patients with primary central nervous system lymphoma ÀÌÁ¤¿Á(¼­¿ïÀÇ´ë )

±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 14:00~14:10 Chemotherapy-free salvage therapy with rituximab, lenalidomide, and poseltinib for the treatment of relapsed or refractory primary central nervous system lymphoma À±»óÀº(¼º±Õ°üÀÇ´ë )

±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 14:10~14:20 Allogeneic Stem Cell Transplantation with 3-days Busulfan plus Fludarabine as Conditioning in Patients with Relapsed or Refractory T-, NK/T-cell lymphomas ÀÌÁöÇö(µ¿¾ÆÀÇ´ë)

±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 14:20~14:30 Decitabine with Gemcitabine, Oxaliplatin for relapsed/refractory peripheral T cell lymphoma º¯ÀÚ¹Î(¼­¿ïÀÇ´ë )

±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 14:30~14:40 Phase II study of Concurrent Tislelizumab and Radiotherapy for treatment-naive, newly diagnosed low-risk extranodal NK/T-cell lymphoma, nasal type À±»óÀº(¼º±Õ°üÀÇ´ë )

±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 14:40~14:50 Phase II study of Lenalidomide Maintenance after Salvage therapy in patients with relapsed and/or refractory non-Hodgkin T-cell lymphoma ±è¼®Áø(¼º±Õ°üÀÇ´ë )

±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 14:50~15:00 Phase II study of Isatuximab and Cemiplimab in relapsed or refractory natural killer/ T-cell lymphoid malignancy ±è¼®Áø(¼º±Õ°üÀÇ´ë )

±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 15:00~15:10 Multicenter, open label, phase I/II study of azacitidine-CHOP for patients with nodal T-cell lymphoma with T-follicular helper phenotype ±è¼®Áø(¼º±Õ°üÀÇ´ë )

±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 15:30~15:45 Real-world outcomes ofpatients with PMBCL in Korea: PET-CT incorporated retrospective analysis ÀÌÁØÈ£(Áß¾ÓÀÇ´ë )

±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 15:45~16:00 International Registry of chronic active EBV infection ±è¼®Áø(¼º±Õ°üÀÇ´ë )

±³À°½Ã°£ 08¿ù 26ÀÏ AȦ 16:00~16:20 Phase 1/2 study of Selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with secondary central nervous system involving relapsed or refractory B-cell non-Hodgkin¡¯s lymphoma: a single arm, open label, multicenter study ¼Û°¡¿µ(Àü³²ÀÇ´ë )

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¸²ÇÁÁ¾¿¬±¸È¸ CISL34 ÀÓ»ó½ÃÇè ¿¬±¸ÀÚ ¸ðÀÓ : 2023-08-26""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2023³â Á¦13ȸ ¼­¿ï´ëÇб³º´¿ø ÀçÈ°ÀÇÇаú ¿¬¼ö°­Á : 2023-08-26
´ÙÀ½±Û ´ëÇѺñ°úÇÐȸ Á¦36ȸ »ï³² ºñ°ú Æ÷·³ : 2023-08-26
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20720 ¼­¿ï 2023³â Á¦7Â÷ ³»°úºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À° : 2024-06-01 0 20 08:58:59
20719 ºÎ»ê Á¦516Â÷ ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ ºÎ»ê¡¤¿ï»ê¡¤°æ³²Áöȸ Çмú´ëȸ : 2024-06-01 0 16 08:57:44
20718 °æ±â Àü¹®½ÉÀå¼Ò»ý¼ú(ACLS Provider) ½Ã¹Ä·¹À̼Ç(2day) : 2024-06-01 0 17 08:56:28
20717 Ãæ³² Á¦16Â÷ Ä¡¸ÅÁø·áÀÇ»ç Àü¹®È­ ±³À° (»ó¹Ý±â_2ÀÏÂ÷) : 2024-06-01 0 16 08:54:50
20716 ¼­¿ï 2024 ´ëÇѵΰæºÎ¿Ü°úÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-01 0 2 08:53:36
20715 ¼­¿ï Á¦41Â÷ ´ëÇÑÁ¢ÃËÇǺο°¡¤¾Ë·¹¸£±âÇÐȸ Çмú´ëȸ : 2024-06-01 0 4 08:52:12
20714 ¼­¿ï ´ëÇÑÃÖ¼Òħ½ÀôÃßÇÐȸ 2024 KOMISS Advanced Spinal Course Symposium & Cadaver Workshop : 2024-06-01 0 2 08:50:52
20713 ¼­¿ï ´ëÇѽÉÀåÇ÷°üÈäºÎ¿Ü°úÇÐȸ Á¦38Â÷ Ãá°èÅëÇÕÇмú´ëȸ ¹× ¿¬¼ö±³À° (1ÀÏÂ÷) : 2024-05-31 0 5 2024-05-25
20712 ºÎ»ê »ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ KSBMB International Conference 2024(3ÀÏÂ÷) : 2024-05-31 0 5 2024-05-25
20711 ºÎ»ê 2024 ´ëÇѾÆÅäÇÇÇǺο°ÇÐȸ ºÎ»ê¿ï»ê°æ³² ±³À°½ÉÆ÷Áö¿ò : 2024-05-31 0 6 2024-05-25
20710 ¼­¿ï (¿Â¶óÀÎ) 2024 ´ëÇÑÀÀ±ÞÀÇ·áÁöµµÀÇ»çÇùÀÇȸ ÁöµµÀÇ»ç Ãá°è¿¬¼ö°­Á : 2024-05-31 0 8 2024-05-25
20709 °æ±â Àü¹®½ÉÀå¼Ò»ý¼ú(ACLS Provider) ½Ã¹Ä·¹À̼Ç(1day) : 2024-05-31 0 1 2024-05-25
20708 ¼­¿ï ´ëÇÑÃÖ¼Òħ½ÀôÃßÇÐȸ 2024 KOMISS Advanced Spinal Course Symposium & Cadaver Workshop : 2024-05-31 0 1 2024-05-25
20707 °æ±â (¿Â¶óÀÎ) ºÐ´ç¼­¿ï´ëÇб³º´¿ø °íÀ§Çè»ê¸ð½Å»ý¾ÆÅëÇÕÄ¡·á ¿ù·ÊÁý´ãȸ : 2024-05-30 0 1 2024-05-25
20706 ºÎ»ê »ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ KSBMB International Conference 2024(2ÀÏÂ÷) : 2024-05-30 0 1 2024-05-25
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷